Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Interact Cardiovasc Thorac Surg ; 6(2): 214-8, 2007 Apr.
Article in English | MEDLINE | ID: mdl-17669814

ABSTRACT

Prospective comparative evaluation of patent V blue, fluorescein and (99m)TC-nanocolloids for intraoperative sentinel lymph node (SLN) mapping during surgery for non-small cell lung cancer (NSCLC). Ten patients with peripherally localised clinical stage I NSCLC underwent thoracotomy and peritumoral subpleural injection of 2 ml of patent V blue dye, 1 ml of 10% fluorescein and 1ml of (99m)Tc-nanocolloids (0.4 mCi). The migration and spatial distribution pattern of the tracers was assessed by direct visualisation (patent V blue), visualisation of fluorescence signalling by a lamp of Wood (fluorescein) and radioactivity counting with a hand held gamma-probe ((99m)Tc-nanocolloids). Lymph nodes at interlobar (ATS 11), hilar (ATS 10) and mediastinal (right ATS 2,4,7; left ATS 5,6,7) levels were systematically assessed every 10 min up to 60 min after injection, followed by lobectomy and formal lymph node dissection. Successful migration from the peritumoral area to the mediastinum was observed for all three tracers up to 60 min after injection. The interlobar lympho-fatty tissue (station ATS 11) revealed an early and preferential accumulation of all three tracers for all tumours assessed and irrespective of the tumour localisation. However, no preferential accumulation in one or two distinct lymph nodes was observed up to 60 min after injection for all three tracers assessed. Intraoperative SLN mapping revealed successful migration of the tracers from the site of peritumoral injection to the mediastinum, but in a diffuse pattern without preferential accumulation in sentinel lymph nodes.


Subject(s)
Carcinoma, Non-Small-Cell Lung/diagnosis , Fluorescein , Fluorescent Dyes , Lung Neoplasms/diagnosis , Lymph Nodes/pathology , Radiopharmaceuticals , Rosaniline Dyes , Sentinel Lymph Node Biopsy , Technetium Tc 99m Aggregated Albumin , Aged , Carcinoma, Non-Small-Cell Lung/diagnostic imaging , Carcinoma, Non-Small-Cell Lung/pathology , Carcinoma, Non-Small-Cell Lung/surgery , Feasibility Studies , Female , Fluorescein/administration & dosage , Fluorescent Dyes/administration & dosage , Humans , Injections, Intralesional , Intraoperative Care , Lung Neoplasms/diagnostic imaging , Lung Neoplasms/pathology , Lung Neoplasms/surgery , Lymph Nodes/diagnostic imaging , Lymph Nodes/surgery , Lymphatic Metastasis/diagnosis , Lymphatic Metastasis/diagnostic imaging , Male , Middle Aged , Neoplasm Staging/methods , Patient Selection , Pneumonectomy , Prospective Studies , Radionuclide Imaging , Radiopharmaceuticals/administration & dosage , Rosaniline Dyes/administration & dosage , Technetium Tc 99m Aggregated Albumin/administration & dosage , Time Factors , Treatment Outcome
2.
Melanoma Res ; 13(5): 511-20, 2003 Oct.
Article in English | MEDLINE | ID: mdl-14512793

ABSTRACT

The technique of sentinel lymph node (SLN) dissection is a reliable predictor of metastatic disease in the lymphatic basin draining the primary melanoma. Reverse transcription-polymerase chain reaction (RT-PCR) is emerging as a highly sensitive technique to detect micrometastases in SLNs, but its specificity has been questioned. A prospective SLN study in melanoma patients was undertaken to compare in detail immunopathological versus molecular detection methods. Sentinel lymphadenectomy was performed on 57 patients, with a total of 71 SLNs analysed. SLNs were cut in slices, which were alternatively subjected to parallel multimarker analysis by microscopy (haematoxylin and eosin and immunohistochemistry for HMB-45, S100, tyrosinase and Melan-A/MART-1) and RT-PCR (for tyrosinase and Melan-A/MART-1). Metastases were detected by both methods in 23% of the SLNs (28% of the patients). The combined use of Melan-A/MART-1 and tyrosinase amplification increased the sensitivity of PCR detection of microscopically proven micrometastases. Of the 55 immunopathologically negative SLNs, 25 were found to be positive on RT-PCR. Notably, eight of these SLNs contained naevi, all of which were positive for tyrosinase and/or Melan-A/MART-1, as detected at both mRNA and protein level. The remaining 41% of the SLNs were negative on both immunohistochemistry and RT-PCR. Analysis of a series of adjacent non-SLNs by RT-PCR confirmed the concept of orderly progression of metastasis. Clinical follow-up showed disease recurrence in 12% of the RT-PCR-positive immunopathology-negative SLNs, indicating that even an extensive immunohistochemical analysis may underestimate the presence of micrometastases. However, molecular analyses, albeit more sensitive, need to be further improved in order to attain acceptable specificity before they can be applied diagnostically.


Subject(s)
Lymphatic Metastasis , Melanoma/diagnosis , Melanoma/pathology , Skin Neoplasms/diagnosis , Skin Neoplasms/pathology , Biomarkers, Tumor , Female , Humans , Immunohistochemistry , Male , Monophenol Monooxygenase/metabolism , Neoplasm Metastasis , RNA/chemistry , Reverse Transcriptase Polymerase Chain Reaction , Sentinel Lymph Node Biopsy/methods , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL
...